Simultaneous or Sequential Multipoint Pacing
Launched by IRCCS POLICLINICO S. DONATO · Sep 28, 2017
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking to compare two different methods of pacing the heart in patients who need cardiac resynchronization therapy (CRT). Specifically, it will study the effects of simultaneous versus sequential pacing on heart function. The goal is to understand how these methods impact the heart's electrical activity and to find the best settings for pacing to improve patients' heart rhythms.
To participate in the trial, you must be at least 18 years old and have a specific heart condition that meets certain medical guidelines, including having a QRS duration longer than 130 milliseconds, which is a measure of how your heart is beating. However, people with certain recent heart problems, severe heart failure, or other serious health issues may not be eligible. If you join the study, you'll be monitored closely to see how well the different pacing methods work. This trial is currently recruiting participants of all genders, so if you or a family member are interested, it could be a good opportunity to learn more about improving heart health.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with approved indication for CRT by European Society of Cardiology/European Heart Rhythm Association guidelines (ESC/EHRA)
- • QRS duration \> 130 ms
- • Ability to provide informed consent for study participation
- • At least 18 years of age
- Exclusion Criteria:
- • Myocardial infarction within 40 days before enrolment
- • NYHA Class IV
- • Tachyarrhythmia caused by temporary or reversible irritation, e.g. poisoning, electrolyte imbalance, hypoxia, sepsis or acute myocardial infarction
- • Such frequent VT or VF that the therapies would cause an unacceptably rapid depletion of the device batteries
- • VT with few or without clinically relevant symptoms
- • VT or VF treatable by surgery
- • Concomitant diseases that would substantially limit a positive prognosis
- • Accelerated intrinsic rhythm
- • Women who are pregnant
About Irccs Policlinico S. Donato
IRCCS Policlinico S. Donato is a leading Italian research hospital and clinical trial sponsor dedicated to advancing medical science through innovative research and patient care. As an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), it is recognized for its commitment to high-quality clinical research and the integration of scientific investigation with clinical practice. The institution specializes in various medical fields, including cardiology, oncology, and neurology, and collaborates with universities and research organizations to facilitate cutting-edge studies. With a focus on improving patient outcomes and contributing to public health, IRCCS Policlinico S. Donato plays a pivotal role in the development of new therapies and treatment protocols.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Donato Milanese, Milano, Italy
Patients applied
Trial Officials
Carlo Pappone, MD
Principal Investigator
IRCCS San Donato University Hospital Policlinico San Donato, Milan, Italy
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials